<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319695</url>
  </required_header>
  <id_info>
    <org_study_id>1234560</org_study_id>
    <nct_id>NCT01319695</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <brief_summary>
    <textblock>
      The use of corifollitropin alfa is superior in terms of pregnancy outcome parameters as
      compared to recombinant follicle stimulating hormone (FSH) during ovarian stimulation
      protocols in women undergoing in vitro fertilisation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>no of oocytes (&gt;2 between groups)</measure>
    <time_frame>at egg recovery, through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate cancellation rate miscarriage rate ectopic pregnancy rate</measure>
    <time_frame>3 weeks after embryo transfer</time_frame>
    <description>The presence of fetal heart at transvaginal ultrasound at 6+2 gestational weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks after embryo transfer</time_frame>
    <description>The presence of fetal heart at ultrasound after 12 gestational weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth rate</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>corifollitropin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant follicle stimulating hormone (FSH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150-300 IU of FSH for ovarian stimulation in women undergoing IVF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corifollitropin alfa</intervention_name>
    <description>100 microg for a group of women weighing &lt;or=60 kg and 150 microg for a group of women weighing &gt;60 kg</description>
    <arm_group_label>corifollitropin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant follicle stimulating hormone (FSH)</intervention_name>
    <description>150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are &gt;18mm</description>
    <arm_group_label>recombinant follicle stimulating hormone (FSH)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-36 years old with a body weight of more than 60 kg up to 90 kg

          -  BMI of 18-32 kg/m2

          -  Menstrual cycle length of 23-35 days

          -  An indication for controlled ovarian stimulation for IVF or ICSI

        Exclusion Criteria:

          -  history of an endocrine abnormality

          -  abnormal outcome of blood biochemistry or hematology

          -  abnormal cervical smear

          -  chronic disease

          -  uterine pathology that interfering with the COS treatment (e.g. fibroids â‰¥ 5 cm)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>3rd Department of Obstetrics and Gynecology, Assisted Reproduction Unit</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Siristatidis Charalampos, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor, Director of the ARU</investigator_title>
  </responsible_party>
  <keyword>corifollitropin alfa</keyword>
  <keyword>FSH ovarian stimulation</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

